Parodi Maurizio Battaglia, Friberg Thomas R, Pedio Marcella, Fiotti Nicola, Di Stefano Giuseppe, Ravalico Giuseppe
Eye Clinic, Azienda Ospedaliero-Universitaria di Trieste, Trieste, Italy.
Ophthalmic Surg Lasers Imaging. 2007 Mar-Apr;38(2):94-9. doi: 10.3928/15428877-20070301-01.
To compare the effects of panretinal photocoagulation (PRP) and photodynamic therapy (PDT) for anterior segment neovascularization secondary to ischemic central retinal vein occlusion (CRVO).
Fifty-seven eyes were randomized to receive standard PRP (19 eyes), selective PRP (20 eyes), or PDT (17 eyes). Selective PRP was performed only when iris neovascularization and/or angle neovascularization showed progression on weekly follow-up. Primary outcome measures were the extension of anterior segment neovascularization and the rate of neovascular glaucoma development. Secondary outcome measures included visual acuity results.
After 12 months of follow-up, iris neovascularization extension was 0.52, 2.55, and 2.27 in the PRP, selective PRP, and PDT groups, respectively. Anterior segment neovascularization extension was 0.57, 1.50, and 1.27 in the PRP, selective PRP, and PDT groups, respectively. Both showed a statistically significant difference in the PRP group. The rate of neovascular glaucoma development was similar in the three groups.
Although PRP was better at determining iris neovascularization and anterior segment neovascularization regression, the similar rate of neovascular glaucoma development found in the three groups indicates that anterior segment neovascularization secondary to ischemic CRVO can also be safely managed using selective PRP or PDT.
比较全视网膜光凝(PRP)和光动力疗法(PDT)治疗缺血性中央视网膜静脉阻塞(CRVO)继发的眼前段新生血管形成的效果。
57只眼被随机分为接受标准PRP(19只眼)、选择性PRP(20只眼)或PDT(17只眼)治疗。仅当虹膜新生血管形成和/或房角新生血管形成在每周随访中出现进展时才进行选择性PRP。主要观察指标为眼前段新生血管形成的扩展情况和新生血管性青光眼的发生率。次要观察指标包括视力结果。
随访12个月后,PRP组、选择性PRP组和PDT组的虹膜新生血管形成扩展分别为0.52、2.55和2.27。PRP组、选择性PRP组和PDT组的眼前段新生血管形成扩展分别为0.57、1.50和1.27。两者在PRP组均显示出统计学显著差异。三组新生血管性青光眼的发生率相似。
虽然PRP在确定虹膜新生血管形成和眼前段新生血管形成消退方面效果更好,但三组中相似的新生血管性青光眼发生率表明,缺血性CRVO继发的眼前段新生血管形成也可使用选择性PRP或PDT安全治疗。